Articles tagged with Eye Diseases
Researchers reviewed published studies and found at least seven patients who experienced devastating harm from unapproved cell therapy. Clinics that offer such treatments often omit poor outcomes in their reports, leading to a significant under-reporting of complications.
The American Academy of Ophthalmology has received a $2 million gift from the Knights Templar Eye Foundation to establish a permanent research fund focused on pediatric ophthalmology. The fund will leverage the IRIS Registry to uncover optimal approaches to prevention and treatment for common and rare eye diseases affecting children.
Researchers at the University of Nottingham have discovered a characteristic of the Descemet membrane that can cause difficulties for surgeons performing corneal transplants. The study found that elastin, an elastic-like fiber, governs the direction of the membrane's roll and may be responsible for its unidirectional behavior.
A study found that inhibiting atypical protein kinase C reduces increased vessel permeability and blocks inflammation, potentially helping protect vision in patients with eye diseases. The therapy has therapeutic potential for diabetic retinopathy, uveitis, and retinal vein and artery occlusions.
A new poll suggests that primary care providers could play a crucial role in promoting vision care for adults age 50 and older. The poll found that nearly a quarter of respondents said they hadn't had their eyes checked by an eye doctor in three years or more, citing cost and lack of insurance coverage as major barriers.
Duke University researchers have developed a handheld probe that can image individual photoreceptors in the eyes of infants, allowing for early detection of eye diseases and brain-related traumas. The new technology uses adaptive optics and is much smaller and faster than previous systems, making it ideal for imaging young children.
Researchers developed a handheld ophthalmology instrument with adaptive optics technology to image individual photoreceptors in the eye, improving diagnosis of eye diseases. The device can capture images of tiny photoreceptors close to the center of the retina, providing insights into brain-related diseases and trauma.
Scientists have detected signs of Alzheimer's disease in the eyes of patients who showed no symptoms, using a non-invasive technique called optical coherence tomography angiography. The study found that patients with elevated levels of Alzheimer's proteins had significant thinning in the center of their retinas.
A new study has found that the thinning of the retina is linked to the loss of brain cells that produce dopamine, a substance that helps control movement. This discovery may lead to a simple eye scan being used to detect Parkinson's disease in its earliest stages.
Researchers at Mount Sinai have successfully restored vision in mice by activating retinal stem cells, which could lead to treatments for patients with blinding diseases. The study found that new rod photoreceptor cells were generated and integrated into the existing retinal structure, restoring function of the visual pathway.
A recent study suggests that glaucoma is not just a pressure-related disease, but also an autoimmune disorder caused by the immune system attacking retinal cells. The researchers found that T cells, which normally target foreign substances, are responsible for progressive retinal degeneration in glaucoma.
The Penn Biomedical Graduate Studies program will award six students with a $2 million fellowship, supporting their work on high-risk projects in biomedical research. The Blavatnik Family Fellowship aims to cultivate outstanding young minds and accelerate critical research.
A significant link was discovered between age-related macular degeneration, diabetic retinopathy, glaucoma and Alzheimer's disease. Patients with these eye conditions were at a 40-50% greater risk of developing Alzheimer's disease compared to similar individuals without these conditions.
Researchers found that bariatric surgery reduces the risk of nerve, kidney and eye disease in patients with type 2 diabetes. The study included over 3,900 patients who underwent bariatric surgery and compared them to a control group of over 11,000 patients who received usual medical care.
A study by University of Utah Health scientists reveals that variation in the genetic modifier Baldspot can influence disease severity in retinitis pigmentosa. The research suggests targeting genes like Baldspot could lead to effective treatments against some disorders.
Researchers found that immune cells called neutrophils may be disrupting the moisturizing glands of the eyelid, causing dry eye. The study suggests that inflammation is a common cause of Meibomian gland dysfunction (MGD) and could lead to new treatment strategies.
UNIGE researchers identified a new gene, MARK3, as the cause of a recessive genetic disorder leading to childhood blindness. The discovery enables accurate diagnosis and may lead to personalized treatment options.
Researchers have made significant progress in developing eye drops to treat age-related macular degeneration (AMD), a leading cause of blindness. The eye drops use cell-penetrating peptides to deliver therapeutic drugs to the retina, offering a convenient and potentially cost-effective alternative to injections.
A 15-year study found that people who eat at least one serving of oranges daily have a 60% reduced risk of developing late macular degeneration. Flavonoids in oranges appear to help prevent against the eye disease.
The Institute of Molecular and Clinical Ophthalmology Basel (IOB) is a pioneering organization developing new therapies for eye diseases. With a strong interdisciplinary approach, IOB combines basic and clinical science to address global challenges like macular degeneration, glaucoma, and myopia.
A new study led by the NIH identified roles for over two dozen genes shared with humans, many linked to human eye disorders, in causing cavefish blindness. Epigenetic regulation mechanisms have been found to play a key role in this process.
A new genetic cause for canine congenital eye disease has been discovered, revealing an unprecedented mode of inheritance linked to maternal genes. The study found that a deletion mutation in the RBP4 gene leads to vitamin A deficiency and blindness in affected dogs.
Cavefish have higher levels of DNA methyltransferase DNMT3B in developing eyes, leading to epigenetic suppression of eye development genes. This process differs from genetic mutations, which are permanent changes in the DNA code.
Machine learning has detected small vessel disease, a common cause of stroke and dementia, in CT scans more accurately than current methods. The software can identify and measure the severity of SVD, enabling clinicians to administer better treatments and predict patients' likelihood of developing dementia.
The MRC Human Genetics Unit at the University of Edinburgh has received £53 million in funding to study human genetics. The unit will investigate genetic variations and their impact on diseases, including those affecting childhood development and cancer.
Tivanisiran, an RNAi-based compound, shows promise in treating dry eye syndrome by improving ocular inflammatory parameters and reducing symptoms. The Phase III Helix study will evaluate its efficacy in over 300 patients across six countries.
A machine learning algorithm diagnosed retinopathy of prematurity (ROP) with comparable or better accuracy than human experts, based on 5,511 images. The study aimed to improve diagnosis, which is currently highly subjective and variable.
A new diagnostic technique has been successfully tested at the University of Bradford, allowing for the isolation of responses from S-cone photoreceptors. This breakthrough could help in the diagnosis of diseases such as Types 1 and 2 diabetes, glaucoma, and high blood pressure.
Sylentis presents preclinical and clinical results for three ophthalmological compounds targeting dry eye syndrome, macular degeneration and eye allergies. The company is a leader in RNAi technology and has developed new treatments for ophthalmological and inflammatory illnesses.
The study, funded by the National Eye Institute, tested oral omega-3 supplementation on patients with dry eye disease. Despite finding some improvement in symptoms and signs, researchers concluded that omega-3 supplements did not show a beneficial effect relative to placebo.
A new randomized clinical trial found that omega-3 fatty acid supplements were no more effective than placebo in alleviating dry eye symptoms. The study enrolled 535 participants and revealed that even the highest dose of omega-3 supplements did not improve outcomes for participants.
A well-controlled trial found that omega-3 fatty acid supplements taken orally proved no better than placebo at relieving symptoms or signs of dry eye. Despite insufficient evidence establishing the effectiveness of omega-3s, clinicians and patients have been inclined to try the supplements for various conditions, including dry eye.
A new 'pen camera' called GonioPEN makes it easier to diagnose patients with glaucoma by detecting the type of glaucoma in a faster and cheaper manner. It causes negligible discomfort and allows doctors or trained technicians to capture high-resolution images of the eye drainage canal with minimal contact.
ICAP has partnered with Ethiopia since 2005, providing critical support in combating malaria. The new five-year project aims to strengthen malaria diagnosis and treatment services, with an eye on long-term elimination of the disease.
Researchers report successful cataract surgeries in 34 Ebola survivors, improving visual acuities from Hand Motions to 20/30 levels. The study provides evidence for safe elective eye surgery in Ebola survivors at risk of uveitis and vision impairment.
A bioengineered retinal implant, composed of human embryonic stem cells, has been shown to halt vision loss in advanced non-neovascular age-related macular degeneration. The implant was well-tolerated and successfully integrated with retinal tissue, demonstrating potential for a new therapy for this progressive disease.
Researchers have identified over 30 different subtypes of retinal ganglion cells, the neurons responsible for processing visual information. This comprehensive understanding will enable the development of more tailored drug development and treatment strategies for neurodegenerative vision disorders.
Researchers at UCSB developed a specially engineered retinal patch using stem cells to treat people with sudden severe sight loss from wet AMD. The study showed improvements in vision, enabling patients to read and perform daily tasks.
A new study found that automated reminder calls improved diabetic eye disease screening rates among low-income minority patients, particularly African Americans. The study showed a significant increase in retinal screenings after receiving robocall reminders, with show rates of 51.6% for African Americans and 61% for Latinos.
A new study published in the American Academy of Ophthalmology journal demonstrates an AI program that detects diabetic eye disease with improved accuracy by incorporating expert feedback from retina specialists. The research provides a groundwork for developing automated systems for screening patients at risk for diabetic retinopathy.
Researchers have developed a gene therapy that successfully treats a form of macular degeneration in dogs, which could lead to a human treatment for an untreatable disease. The therapy works by repairing the connection between retinal cells, restoring vision.
The NIH-led AMD Ryan Initiative Study (ARIS) will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). Researchers aim to identify biomarkers of disease progression and develop therapies to halt its progression.
Researchers developed an AI-based computational tool to screen patients for common retinal diseases, achieving over 95% accuracy in diagnosis. The tool also showed promise in diagnosing childhood pneumonia with over 90% accuracy, highlighting its potential applications in healthcare.
Two novel ocular hypotensive agents, netarsudil and latanoprostene bunod, have been approved for use in humans, reducing intraocular pressure with lasting results. These breakthrough drugs also show promise for treating dry eye disease and delivering ophthalmic drugs via microneedles.
Researchers found that very long-chain meibum is essential for preventing dry eye disease. Mice with deleted Elovl1 gene developed cloudy corneas and signs of dry eye disease after five months.
A new study by Anglia Ruskin University found that people with diabetes are twice as likely to develop cataract as the general population. The relative risk is highest among individuals aged between 45 and 54, who are up to 5.7 times more likely to be diagnosed with cataract than their healthy counterparts.
Scientists at Joslin Diabetes Center found a connection between eye damage and cardiovascular disease in people with type 1 diabetes, suggesting shared biological mechanisms. The study also showed that kidney disease was not necessarily linked to cardiovascular disease, challenging previous assumptions.
A $2.2 million grant will fund research into genetically controlled breaks in the external limiting membrane, which could lead to new prevention and treatment strategies for ESCS and other retinal diseases. The study aims to understand how these breaks contribute to disease progression.
Researchers from Osaka University have identified an antibody that alleviates symptoms in neuromyelitis optica in rats by suppressing RGMa. The study uses a new localized animal model to investigate the correlation between inflammation and motor function disruption.
Researchers at University of Wisconsin-Madison have developed an improved gene delivery tactic for treating glaucoma, a leading blinding disease. The new method doubles the transfer of genes entering target cells and spreads them more uniformly across the trabecular meshwork tissue.
Restasis, approved by FDA in 2003, shows no direct improvement in symptoms but is marketed as treatment for chronic dry eye disease. The drug's extensive marketing campaign created a perceived need, driving $8.8 billion in US sales between 2009 and 2015.
Researchers at Aalto University developed a new plasmonic biosensor that detects diseased exosomes with high sensitivity using the naked eye. This breakthrough technology enables rapid recognition of inflammatory bowel diseases, cancer, and other conditions, allowing for timely treatment initiation.
A new compound developed by Sylentis can penetrate the retina to treat age-related macular degeneration and diabetic retinopathy with ophthalmic drops. The drug blocks the formation of new blood vessels and has shown efficacy in animal models, offering a promising alternative to painful injections.
A deep learning computing system developed to classify retinal images can detect diabetic retinopathy, glaucoma, and age-related macular degeneration with high accuracy. The study used 494,661 retinal images from diverse patient populations.
This special issue highlights innovations in MALDI mass spectrometry for characterizing proteomes, detecting analytes, and screening non-covalent binding of small molecules to target proteins. MALDI imaging is used to study diseases and therapeutics, including the distribution of glycosphingolipids in a Gaucher Disease model mouse brain.
A new review article examines the effectiveness of lipid-based products, including liposome lid sprays and emulsion eye drops, in treating dry eye disease. The studies found that these products provide immediate relief of symptoms and improve the structure and stability of the tear film lipid layer.
The University of Liverpool's Ultra-Sensitive Optical Coherence Tomography (Ultra-OCT) system is developing a state-of-the-art imaging technology to revolutionise the detection, diagnosis, and management of corneal eye conditions. The system boasts a resolution of 2 micrometres and can scan 1,000 times faster than existing OCT machines.
Optic nerve hypoplasia is a leading cause of childhood blindness in developed nations, and researchers have discovered the biological mechanism behind it. The condition affects brain growth during development, particularly with the CASK gene, which helps provide architectural support for neuronal communication.
Researchers from Hadassah-Hebrew University Medical Center and Bascom Palmer Eye Institute conducted two clinical trials using human embryonic stem cells to treat dry macular degeneration, a leading cause of new blindness. The studies showed that stem cell injection into the eye replaced damaged cells and improved vision in some patients.
A new neurostimulator device inserted into the nose has shown significant relief for people suffering from dry eyes, increasing tear production and producing a complete tear. Researchers tested 97 patients with moderate to severe dry eye and reported no side effects.